Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Metra, Marco;
2021-01-01
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Bhatt DL, Szarek M, Steg PG, et al., and Pitt B. SOLOIST. N Engl J Med. 2020 Online.pdf
solo utenti autorizzati
Tipologia:
Documento in Pre-print
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
670.38 kB
Formato
Adobe PDF
|
670.38 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
